Abeona Therapeutics Q2 2021 Earnings Report

Announced financial results for the second quarter 2021 and recent business progress.

Key Takeaways

Abeona Therapeutics reported financial results for the second quarter of 2021, with a net loss of $15.2 million. The company's cash, cash equivalents, and short-term investments totaled $77.6 million as of June 30, 2021. R&D spending was $7.4 million and G&A spending was $5.5 million for the quarter.

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study.

Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA; Alignment with FDA on primary study endpoint

Focusing resources on completing EB-101 and ABO-102 pivotal, registration-enabling studies

Net cash used in operating activities was $11.5 million for the second quarter of 2021.